肾病住院患者药物相关问题的发生率和影响因素:一项前瞻性单一中心研究。

IF 4.4 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Frontiers in Pharmacology Pub Date : 2024-10-30 eCollection Date: 2024-01-01 DOI:10.3389/fphar.2024.1436561
Guoguang Gu, Yanping Li, Yunyun Hu, Hengyi Zhao, Xingdong Wang, Xiaomin Li, Xinran Zhang, Hong Zhu, Xiaohua Dai, Xingxing Liu, Liyan Miao, Jianguo Zhu, Yongfu Hang
{"title":"肾病住院患者药物相关问题的发生率和影响因素:一项前瞻性单一中心研究。","authors":"Guoguang Gu, Yanping Li, Yunyun Hu, Hengyi Zhao, Xingdong Wang, Xiaomin Li, Xinran Zhang, Hong Zhu, Xiaohua Dai, Xingxing Liu, Liyan Miao, Jianguo Zhu, Yongfu Hang","doi":"10.3389/fphar.2024.1436561","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>To investigate the prevalence and influencing factors of drug-related problems (DRPs) in inpatients with kidney disease to provide reference data for pharmaceutical care.</p><p><strong>Methods: </strong>The basic information, diagnoses, and medication reconciliation (MR) of inpatients in the Department of Nephrology at our hospital between October 2020 and September 2021 were collected. The Chinese-modified DRP version based on the PCNE classification (Version 9.1) was used to assess, intervene and statistically analyze the results of the patients' DRPs. The influence factor of DRPs in inpatients with kidney disease was analyzed by the multivariate binary logistic regression.</p><p><strong>Results: </strong>Of 623 patients included in this study, 132 (21.80%) had DRPs. The prevalence of anemia was significantly higher in patients with DRPs than those without DRPs (43.18% vs. 28.72%, <i>p</i> < 0.05), the mean number of drug types consumed (7.25 ± 3.44 with DRPs vs. 5.93 ± 3.58 without DRPs, <i>p</i> < 0.05) and the proportion of ≥5 drugs (%) (79.55% with DRPs vs 58.04% without DRPs, <i>p</i> < 0.05) were significantly increased. In addition, the prevalence of hypertension (76.52% vs. 68.64%), diabetes (27.27% vs. 22.20%) and hyperuricemia (16.67% vs. 13.65%) in DRP patients were higher than those without DRPs, but there was no statistical difference (<i>p</i> > 0.05). The logistic regression analysis showed that patients with anemia (OR = 1.702, 95%CI: 1.146-2.529, <i>p</i> = 0.008), average number of medication types taken (OR = 1.089, 95%CI: 1.034-1.147, <i>p</i> = 0.001) significantly increased the risk of DRPs. The distribution of harm levels was as follows: 78 problems (59.09%) were level C, 29 (21.97%) were level B, 10 (7.58%) were level D, 7 (5.30%) were level A, 7 (5.30%) were level E, and 1 (0.76%) were level F. All DRPs were resolved after 128 interventions.</p><p><strong>Conclusion: </strong>Renal anemia, the average number of drug varieties consumed, and the proportion of ≥5 drugs are associated with the occurrence of DRPs. Pharmacists conducting MR services can reduce DRPs of inpatients in the department of nephrology and ensure patient drug safety.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1436561"},"PeriodicalIF":4.4000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11557342/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prevalence and influence factor of drug-related problems in inpatients with kidney disease: a prospective single central study.\",\"authors\":\"Guoguang Gu, Yanping Li, Yunyun Hu, Hengyi Zhao, Xingdong Wang, Xiaomin Li, Xinran Zhang, Hong Zhu, Xiaohua Dai, Xingxing Liu, Liyan Miao, Jianguo Zhu, Yongfu Hang\",\"doi\":\"10.3389/fphar.2024.1436561\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>To investigate the prevalence and influencing factors of drug-related problems (DRPs) in inpatients with kidney disease to provide reference data for pharmaceutical care.</p><p><strong>Methods: </strong>The basic information, diagnoses, and medication reconciliation (MR) of inpatients in the Department of Nephrology at our hospital between October 2020 and September 2021 were collected. The Chinese-modified DRP version based on the PCNE classification (Version 9.1) was used to assess, intervene and statistically analyze the results of the patients' DRPs. The influence factor of DRPs in inpatients with kidney disease was analyzed by the multivariate binary logistic regression.</p><p><strong>Results: </strong>Of 623 patients included in this study, 132 (21.80%) had DRPs. The prevalence of anemia was significantly higher in patients with DRPs than those without DRPs (43.18% vs. 28.72%, <i>p</i> < 0.05), the mean number of drug types consumed (7.25 ± 3.44 with DRPs vs. 5.93 ± 3.58 without DRPs, <i>p</i> < 0.05) and the proportion of ≥5 drugs (%) (79.55% with DRPs vs 58.04% without DRPs, <i>p</i> < 0.05) were significantly increased. In addition, the prevalence of hypertension (76.52% vs. 68.64%), diabetes (27.27% vs. 22.20%) and hyperuricemia (16.67% vs. 13.65%) in DRP patients were higher than those without DRPs, but there was no statistical difference (<i>p</i> > 0.05). The logistic regression analysis showed that patients with anemia (OR = 1.702, 95%CI: 1.146-2.529, <i>p</i> = 0.008), average number of medication types taken (OR = 1.089, 95%CI: 1.034-1.147, <i>p</i> = 0.001) significantly increased the risk of DRPs. The distribution of harm levels was as follows: 78 problems (59.09%) were level C, 29 (21.97%) were level B, 10 (7.58%) were level D, 7 (5.30%) were level A, 7 (5.30%) were level E, and 1 (0.76%) were level F. All DRPs were resolved after 128 interventions.</p><p><strong>Conclusion: </strong>Renal anemia, the average number of drug varieties consumed, and the proportion of ≥5 drugs are associated with the occurrence of DRPs. Pharmacists conducting MR services can reduce DRPs of inpatients in the department of nephrology and ensure patient drug safety.</p>\",\"PeriodicalId\":12491,\"journal\":{\"name\":\"Frontiers in Pharmacology\",\"volume\":\"15 \",\"pages\":\"1436561\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-10-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11557342/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fphar.2024.1436561\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2024.1436561","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的:探讨肾脏病住院患者药物相关问题(DRPs)的发生率及影响因素,为药物治疗提供参考数据:方法:收集我院肾内科 2020 年 10 月至 2021 年 9 月期间住院患者的基本信息、诊断和药物对账(MR)情况。采用基于PCNE分类的中国修订版DRP(9.1版)对患者的DRP进行评估、干预和统计分析。通过多变量二元逻辑回归分析了DRP对肾病住院患者的影响因素:本研究纳入的 623 名患者中,132 人(21.80%)有 DRPs。有 DRP 的患者贫血发生率明显高于无 DRP 的患者(43.18% vs. 28.72%,P < 0.05),平均用药种类数(有 DRP 的患者为 7.25 ± 3.44 vs. 无 DRP 的患者为 5.93 ± 3.58,P < 0.05)和≥5 种药物的比例(%)(有 DRP 的患者为 79.55% vs. 无 DRP 的患者为 58.04%,P < 0.05)均明显增加。此外,DRP 患者的高血压患病率(76.52% vs. 68.64%)、糖尿病患病率(27.27% vs. 22.20%)和高尿酸血症患病率(16.67% vs. 13.65%)均高于无 DRP 患者,但无统计学差异(P > 0.05)。逻辑回归分析显示,贫血患者(OR = 1.702,95%CI:1.146-2.529,p = 0.008)、平均服药种类数(OR = 1.089,95%CI:1.034-1.147,p = 0.001)显著增加了 DRP 的风险。危害程度分布如下78个问题(59.09%)为C级,29个问题(21.97%)为B级,10个问题(7.58%)为D级,7个问题(5.30%)为A级,7个问题(5.30%)为E级,1个问题(0.76%)为F级,所有DRP问题均在128次干预后得到解决:结论:肾性贫血、平均用药品种数和用药≥5 种的比例与 DRP 的发生有关。药剂师开展 MR 服务可减少肾内科住院患者的 DRP,确保患者用药安全。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Prevalence and influence factor of drug-related problems in inpatients with kidney disease: a prospective single central study.

Aims: To investigate the prevalence and influencing factors of drug-related problems (DRPs) in inpatients with kidney disease to provide reference data for pharmaceutical care.

Methods: The basic information, diagnoses, and medication reconciliation (MR) of inpatients in the Department of Nephrology at our hospital between October 2020 and September 2021 were collected. The Chinese-modified DRP version based on the PCNE classification (Version 9.1) was used to assess, intervene and statistically analyze the results of the patients' DRPs. The influence factor of DRPs in inpatients with kidney disease was analyzed by the multivariate binary logistic regression.

Results: Of 623 patients included in this study, 132 (21.80%) had DRPs. The prevalence of anemia was significantly higher in patients with DRPs than those without DRPs (43.18% vs. 28.72%, p < 0.05), the mean number of drug types consumed (7.25 ± 3.44 with DRPs vs. 5.93 ± 3.58 without DRPs, p < 0.05) and the proportion of ≥5 drugs (%) (79.55% with DRPs vs 58.04% without DRPs, p < 0.05) were significantly increased. In addition, the prevalence of hypertension (76.52% vs. 68.64%), diabetes (27.27% vs. 22.20%) and hyperuricemia (16.67% vs. 13.65%) in DRP patients were higher than those without DRPs, but there was no statistical difference (p > 0.05). The logistic regression analysis showed that patients with anemia (OR = 1.702, 95%CI: 1.146-2.529, p = 0.008), average number of medication types taken (OR = 1.089, 95%CI: 1.034-1.147, p = 0.001) significantly increased the risk of DRPs. The distribution of harm levels was as follows: 78 problems (59.09%) were level C, 29 (21.97%) were level B, 10 (7.58%) were level D, 7 (5.30%) were level A, 7 (5.30%) were level E, and 1 (0.76%) were level F. All DRPs were resolved after 128 interventions.

Conclusion: Renal anemia, the average number of drug varieties consumed, and the proportion of ≥5 drugs are associated with the occurrence of DRPs. Pharmacists conducting MR services can reduce DRPs of inpatients in the department of nephrology and ensure patient drug safety.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Frontiers in Pharmacology
Frontiers in Pharmacology PHARMACOLOGY & PHARMACY-
CiteScore
7.80
自引率
8.90%
发文量
5163
审稿时长
14 weeks
期刊介绍: Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信